EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936)

Amelia Barcellini iD, Silvia Molinelli, Alessandro Vanoli, Viviana Vitolo, Piero Fossati, Alessandro Vai iD, Anna Pagani, Frediano Inzani, Mattia Pecorilla, Giovanni Butturini, Catherine Klersy, Lorenzo Preda und 3 weitere

Tumori Journal · 2024

DOI: 10.1177/03008916241291341 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Tumori Journal, 2024. Verfasst von Amelia Barcellini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

There is debate about the optimal management of borderline resectable (bRe) and resectable (Re) pancreatic ductal adenocarcinoma (PDAC). Both preclinical and clinical evidence showed that carbon ion radiotherapy (CIRT) produces superior control on radioresistant histologies compared to conventional photon beam radiotherapy (RT). However, so far there is a lack of data concerning the integration of CIRT in a multimodal approach with chemotherapy and surgery for bRe/Re.

Methods

We recently presented the first analysis of a multicenter prospective phase II clinical study aimed at assessing the feasibility and effectiveness of a neoadjuvant chemotherapy + short course of CIRT followed by surgery and adjuvant chemotherapy in the management of bRe/Re PDAC. The study was terminated early due to low patient enrollment.Herein, we reported a post-hoc analysis focusing on toxicity, dosimetry and translational assessment.

Results

In our experience, CIRT can be integrated into a multimodal treatment strategy for bRe/Re PDAC, alongside chemotherapy and surgery. A case of fatal liver failure occurring three months post-surgery has been documented, likely related to the combination approach. Although the treatment plans were satisfactory according to the Local Effect Model (LEM) model, recalculations using the modified Microdosimetric Kinetic Model (mMKM) revealed suboptimal target coverage. Additionally, we observed an increased expression of PD-L1 following CIRT.

Conclusions

This multimodal approach was well tolerated; however, clinicians should carefully monitor for vascular disorders during follow-up and further investigate surgical techniques after CIRT. The increased PD-L1 expression supports the immunogenic effects of particle therapy and lays the groundwork for future studies. To enhance the therapeutic ratio of CIRT treatments, integrating LET-d based objectives into the plan optimization process should be considered. Trial Registration Number: ClinicalTrials.gov Identifier: NCT03822936

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyHumansProspective StudiesMaleFemaleMiddle AgedAgedCarcinoma, Pancreatic DuctalHeavy Ion RadiotherapyCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Stichwörter der Autor:innen

Carbon ion radiotherapyLETPDL1borderline/resectable pancreatic adenocarcinomas

Autor:innen und Institutionen

  • Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
  • Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
  • Medical Physics Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
  • Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, Pavia, Italy.
  • Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Department of Radiation Oncology, MedAustron Ion Therapy Center, Wiener Neustadt, Austria.

ORCID-Profile: Amelia Barcellini, Alessandro Vai, Ester Orlandi

Zitieren

APA

Barcellini, A., Molinelli, S., Vanoli, A., Vitolo, V., Fossati, P., Vai, A., Pagani, A., Inzani, F., Pecorilla, M., Butturini, G., Klersy, C., Preda, L., Facoetti, A., Valvo, F., & Orlandi, E. (2024). Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936). Tumori Journal. https://doi.org/10.1177/03008916241291341

Vancouver

Barcellini A, Molinelli S, Vanoli A, Vitolo V, Fossati P, Vai A, et al. Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936). Tumori Journal. 2024. doi:10.1177/03008916241291341

BibTeX
@article{Barcellini2024,
  author = {Barcellini, Amelia and Molinelli, Silvia and Vanoli, Alessandro and Vitolo, Viviana and Fossati, Piero and Vai, Alessandro and Pagani, Anna and Inzani, Frediano and Pecorilla, Mattia and Butturini, Giovanni and Klersy, Catherine and Preda, Lorenzo and Facoetti, Angelica and Valvo, Francesca and Orlandi, Ester},
  title = {Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase II clinical study (NCT03822936)},
  journal = {Tumori Journal},
  year = {2024},
  doi = {10.1177/03008916241291341}
}
Kostenlos starten →